Pediatric acute myeloid leukemia

Expert Review of Anticancer Therapy

Volumn 12, Issue 3, 2012, Pages 405-413

  Kaspers, Gertjan J L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

allogeneic stem cell transplantation; childhood; children; clofarabine; gemtuzumab ozogamicin (Mylotarg ); late effects; liposomal daunorubicin (DaunoXome ); minimal residual disease; tailored therapy; targeted therapy

Indexed keywords

AMSACRINE; ANTHRACYCLINE; ANTHRAQUINONE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; MAINTENANCE CHEMOTHERAPY; OUTCOME ASSESSMENT; RECURRENCE FREE SURVIVAL; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME;

ANTHRACYCLINES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS AS TOPIC; COMPLEMENTARY THERAPIES; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; NEOPLASM, RESIDUAL; RECURRENCE; SURVIVAL RATE; THERAPIES, INVESTIGATIONAL; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84857865773     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.1     Document Type: Review

References (42)

1. Abrahamsson J, Forestier E, Heldrup J et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J. Clin. Oncol. 29, 310-315 (2011).
2. Creutzig U, Zimmermann M, Dworzak M et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br. J. Haematol. 149, 399-409 (2010).
3. Gibson BE, Webb DK, Howman AJ, de Graaf SS, Harrison CJ, Wheatley K. Results of a randomized trial in children with acute myeloid leukaemia: Medical research council AML12 trial. Br. J. Haematol. 155, 366-376 (2011).
4. Rubnitz JE, Inaba H, Dahl G et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol. 11, 543-552 (2010).
5. Tsukimoto I, Tawa A, Horibe K et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J. Clin. Oncol. 27, 4007-4013 (2009).
6. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: International progress and future directions. Leukemia 19, 2025-2029 (2005).
7. Leung W, Hudson MM, Strickland DK et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J. Clin. Oncol. 18, 3273-3279 (2000).
8. Molgaard-Hansen L, Glosli H, Jahnukainen K et al. Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO-AML study. Pediatr. Blood Cancer 57, 1222-1229 (2011).
9. Gibson BE, Wheatley K, Hann IM et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19, 2130-2138 (2005).
10. Horan JT, Alonzo TA, Lyman GH et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: The Children's Oncology Group. J. Clin. Oncol. 26, 5797-5801 (2008).
11. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 116, 2205-2214 (2010).
12. Reinhardt D, Kremens B, Zimmermann M et al. No improvement of overall-survival in children with high-risk acute myeloid leukemia by stem cell transplantation in 1st Abrahamsson J, Forestier E, Heldrup J et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J. Clin. Oncol. 29, 310-315 (2011).
13. Creutzig U, Zimmermann M, Dworzak M et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br. J. Haematol. 149, 399-409 (2010).
14. Gibson BE, Webb DK, Howman AJ, de Graaf SS, Harrison CJ, Wheatley K. Results of a randomized trial in children with acute myeloid leukaemia: Medical research council AML12 trial. Br. J. Haematol. 155, 366-376 (2011).
15. Rubnitz JE, Inaba H, Dahl G et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol. 11, 543-552 (2010).
16. Tsukimoto I, Tawa A, Horibe K et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J. Clin. Oncol. 27, 4007-4013 (2009).
17. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: International progress and future directions. Leukemia 19, 2025-2029 (2005).
18. Leung W, Hudson MM, Strickland DK et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J. Clin. Oncol. 18, 3273-3279 (2000).
19. Molgaard-Hansen L, Glosli H, Jahnukainen K et al. Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO-AML study. Pediatr. Blood Cancer 57, 1222-1229 (2011).
20. Gibson BE, Wheatley K, Hann IM et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19, 2130-2138 (2005).
21. Horan JT, Alonzo TA, Lyman GH et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: The Children's Oncology Group. J. Clin. Oncol. 26, 5797-5801 (2008).
22. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 116, 2205-2214 (2010).
23. Reinhardt D, Kremens B, Zimmermann M et al. No improvement of overall-survival in children with high-risk acute myeloid leukemia by stem cell transplantation in 1st acute myeloid leukaemia. Br. J. Haematol. 130, 801-803 (2005).
24. Liang DC, Shih LY, Huang CF et al. CEBPa mutations in childhood acute myeloid leukemia. Leukemia 19, 410-414 (2005).
25. Hollink IH, Zwaan CM, Zimmermann M et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 23, 262-270 (2009).
26. Hollink IH, van den Heuvel-Eibrink MM, Rentsen-Peters ST et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 96, 384-392 (2011).
27. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 113, 5951-5960 (2009).
28. Bachas C, Schuurhuis GJ, Hollink IH et al. High-frequency Type 1/2 mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: Implications for personalized medicine. Blood 116, 2752-2758 (2010).
29. Cloos J, Goemans BF, Hess CJ et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20, 1217-1220 (2006).
30. Stahnke K, Boos J, der-Gotze C, Ritter J, Zimmermann M, Creutzig U. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 12, 1534-1538 (1998).
31. Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML-10 trial. MRC Childhood Leukaemia Working Party. Leukemia 13, 25-31 (1999).
32. Kaspers GJ, Zimmermann M, Reinhardt D et al. Prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: Results from the international study Relapsed AML 2001/01. Blood (ASH Annual Meeting Abstracts) 110, 1843 (2007).
33. Webb DK. Treatment of relapsed AML in children. Br. J. Haematol. 104, 420-421 (1999).
34. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: Towards high-quality cure of all patients. Haematologica 92, 1519-1532 (2007).
35. Hijiya N, Thomson B, Isakoff MS et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 118, 6043-6049 (2011).
36. Jeha S, Razzouk B, Rytting M et al. Phase 2 study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J. Clin. Oncol. 27, 4392-4397 (2009).
37. Zwaan CM, Reinhardt D, Zimmerman M et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: Results of a Phase 2 study. Br. J. Haematol. 148, 768-776 (2010).
38. Inaba H, Rubnitz JE, Coustan-Smith E et al. Phase 1 pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J. Clin. Oncol. 29, 3293-3300 (2011).
39. Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. Clin. Immunol. 133, 171-178 (2009).
40. Becton D, Dahl GV, Ravindranath Y et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group study 9421. Blood 107, 1315-1324 (2006).
41. Lange BJ, Smith FO, Feusner J et al. Outcomes in CCG-2961, a Children's Oncology Group Phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 111, 1044-1053 (2008).
42. Cooper TM, Franklin J, Gerbing RB et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group. Cancer 118(3), 761-769 (2012).